Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Jan Willem B, de Groot"'
Autor:
Lindsay V. M. Leek, Jessica C. L. Notohardjo, Karlijn de Joode, Eline L. Velker, John B. A. G. Haanen, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Jan Willem B. de Groot, Ellen Kapiteijn, Franchette W. P. J. van den Berkmortel, Hans M. Westgeest, Tanja D. de Gruijl, Valesca P. Retel, Edwin Cuppen, Astrid A. M. van der Veldt, Mariette Labots, Emile E. Voest, Joris van de Haar, Alfons J. M. van den Eertwegh
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract We evaluated the prognostic value of hypoalbuminemia in context of various biomarkers at baseline, including clinical, genomic, transcriptomic, and blood-based markers, in patients with metastatic melanoma treated with anti-PD-1 monotherapy
Externí odkaz:
https://doaj.org/article/0b86698c5e3b43c28f9ef4dd875f5025
Autor:
Kalijn F. Bol, Gerty Schreibelt, Martine Bloemendal, Wouter W. van Willigen, Simone Hins-de Bree, Anna L. de Goede, Annemiek J. de Boer, Kevin J. H. Bos, Tjitske Duiveman-de Boer, Michel A. M. Olde Nordkamp, Tom G. M. van Oorschot, Carlijn J. Popelier, Jeanne M. Pots, Nicole M. Scharenborg, Mandy W. M. M. van de Rakt, Valeska de Ruiter, Wilmy S. van Meeteren, Michelle M. van Rossum, Sandra J. Croockewit, Bouke J. Koeneman, Jeroen H. A. Creemers, Inge M. N. Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A. van der Veldt, Dirk J. van Grünhagen, Johanna E. M. Werner, Johannes J. Bonenkamp, John B. A. G. Haanen, Marye J. Boers-Sonderen, Rutger H. T. Koornstra, Martijn F. Boomsma, Erik H. J. Aarntzen, Martin Gotthardt, James Nagarajah, Theo J. M. de Witte, Carl G. Figdor, Johannes H. W. de Wilt, Johannes Textor, Jan Willem B. de Groot, Winald R. Gerritsen, I. Jolanda M. de Vries
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were r
Externí odkaz:
https://doaj.org/article/245269452ff04a81b46a9a6846fb6516
Autor:
Olivier J. van Not, Alfons J.M. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Jesper van Breeschoten, Franchette W.P.J. van den Berkmortel, Jan-Willem B. de Groot, Geke A.P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Manja Bloem, Melissa M. De Meza, Djura Piersma, Rozemarijn S. van Rijn, Marion A.M. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Willeke A.M. Blokx, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk
Publikováno v:
EClinicalMedicine, Vol 69, Iss , Pp 102485- (2024)
Summary: Background: The prognosis of advanced melanoma patients has significantly improved over the years. We aimed to evaluate the survival per year of diagnosis. Methods: All systemically treated patients diagnosed with advanced melanoma from 2013
Externí odkaz:
https://doaj.org/article/09267a9e520444ec9384e855653228ee
Autor:
Birgit S. Geurts, Thomas W. Battaglia, J. Maxime van Berge Henegouwen, Laurien J. Zeverijn, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Frans L. Opdam, Maja J. A. de Jonge, Geert A. Cirkel, Mariette Labots, Ann Hoeben, Emile D. Kerver, Adriaan D. Bins, Frans G.L. Erdkamp, Johan M. van Rooijen, Danny Houtsma, Mathijs P. Hendriks, Jan-Willem B. de Groot, Henk M. W. Verheul, Hans Gelderblom, Emile E. Voest
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the Drug Rediscovery Protocol (DRUP
Externí odkaz:
https://doaj.org/article/0e6af27c660548eab8d0d86d81fe251d
Autor:
Annegien Broeks, Sofie Wilgenhof, John B A G Haanen, Karolina Sikorska, Christian U Blank, Judith M Versluis, Jan Willem B de Groot, Esmee P Hoefsmit, Elisa A Rozeman, Petros Dimitriadis, Aysegul Sari, Daan van den Broek, Disha Rao, Ruben Lacroix, Lindsay G Grijpink-Ongering, Marta Lopez-Yurda, Birthe C Heeres, Bart A van de Wiel, Claudie Flohil, Stijn W T P J Heijmink, Marieke A Vollebergh, Johannes V van Thienen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Continuous combination of MAPK pathway inhibition (MAPKi) and anti-programmed death-(ligand) 1 (PD-(L)1) showed high response rates, but only limited improvement in progression-free survival (PFS) at the cost of a high frequency of treatme
Externí odkaz:
https://doaj.org/article/85f4bb454d4548b7b0eddc4aff9da5e2
Autor:
Esther N. Pijnappel, Melinda Schuurman, Anna D. Wagner, Judith de Vos-Geelen, Lydia G. M. van der Geest, Jan-Willem B. de Groot, Bas Groot Koerkamp, Ignace H. J. T. de Hingh, Marjolein Y. V. Homs, Geert-Jan Creemers, Geert A. Cirkel, Hjalmar C. van Santvoort, Olivier R. Busch, Marc G. Besselink, Casper H.J. van Eijck, Johanna W. Wilmink, Hanneke W. M. van Laarhoven
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundBiological sex, gender and age have an impact on the incidence and outcome in patients with metastatic pancreatic cancer. The aim of this study is to investigate whether biological sex, gender and age are associated with treatment allocatio
Externí odkaz:
https://doaj.org/article/4f79caf484fb429aad6b52f77ca218c8
Autor:
Fleur van der Sijde, Zakia Azmani, Marc G. Besselink, Bert A. Bonsing, Jan Willem B. de Groot, Bas Groot Koerkamp, Brigitte C. M. Haberkorn, Marjolein Y. V. Homs, Wilfred F. J. van IJcken, Quisette P. Janssen, Martijn P. Lolkema, Saskia A. C. Luelmo, Leonie J. M. Mekenkamp, Dana A. M. Mustafa, Ron H. N. van Schaik, Johanna W. Wilmink, Eveline E. Vietsch, Casper H. J. van Eijck
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Biomarkers predicting treatment response may be used to stratify pancreatic ductal adenocarcinoma (PDAC) patients for therapy. The aim of this study was to identify circulating tumor DNA (ctDNA) mutations that associate with tumor progres
Externí odkaz:
https://doaj.org/article/56708d8cb614448a80bd2b337bdf4405
Autor:
Melissa M. de Meza, Willeke A. M. Blokx, Han J. Bonenkamp, Cristian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers‐Sonderen, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense‐Den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Alfons J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
Publikováno v:
International Journal of Cancer, 153, 2, pp. 389-398
de Meza, M M, Blokx, W A M, Bonenkamp, H J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ', International Journal of Cancer, vol. 153, no. 2, pp. 389-398 . https://doi.org/10.1002/ijc.34485
International Journal of Cancer, 153(2), 389-398. Wiley-Liss Inc.
International Journal of Cancer, 153, 389-398
International Journal of Cancer. Wiley
International Journal of Cancer, 153, 389-398. Wiley
de Meza, M M, Blokx, W A M, Bonenkamp, H J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ', International Journal of Cancer, vol. 153, no. 2, pp. 389-398 . https://doi.org/10.1002/ijc.34485
International Journal of Cancer, 153(2), 389-398. Wiley-Liss Inc.
International Journal of Cancer, 153, 389-398
International Journal of Cancer. Wiley
International Journal of Cancer, 153, 389-398. Wiley
Contains fulltext : 292870.pdf (Publisher’s version ) (Open Access) Few clinical trials address efficacy of adjuvant systemic treatment in patients with in-transit melanoma (ITM). This study describes adjuvant systemic therapy of ITM patients beyon
Autor:
Isabella A. J. van Duin, Sjoerd G. Elias, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, Willeke A. M. Blokx, Paul J. van Diest, Tim Leiner, Joost J. C. Verhoeff, Rik J. Verheijden, Olivier J. van Not, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, John B. A. G. Haanen, Geke A. P. Hospers, Anna M. Kamphuis, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Marion A. M. Stevense‐den Boer, Marye J. Boers‐Sonderen, Ellen Kapiteijn, Karijn P. M. Suijkerbuijk
Publikováno v:
van Duin, I A J, Elias, S G, van den Eertwegh, A J M, de Groot, J W B, Blokx, W A M, van Diest, P J, Leiner, T, Verhoeff, J J C, Verheijden, R J, van Not, O J, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Haanen, J B A G, Hospers, G A P, Kamphuis, A M, Piersma, D, van Rijn, R S, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Stevense-den Boer, M A M, Boers-Sonderen, M J, Kapiteijn, E & Suijkerbuijk, K P M 2023, ' Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma ', International Journal of Cancer, vol. 152, no. 12, pp. 2493-2502 . https://doi.org/10.1002/ijc.34479
International Journal of Cancer, 152(12), 2493-2502. Wiley
International Journal of Cancer, 152(12), 2493-2502. Wiley-Liss Inc.
International Journal of Cancer, 152(12), 2493-2502. Wiley
International Journal of Cancer, 152(12), 2493-2502. Wiley-Liss Inc.
Since the introduction of BRAF(/MEK) inhibition and immune checkpoint inhibition (ICI), the prognosis of advanced melanoma has greatly improved. Melanoma is known for its remarkably long time to first distant recurrence (TFDR), which can be decades i
Autor:
Jesper van Breeschoten, Alfons J.M. van den Eertwegh, Doranne L. Hilarius, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Damjan Manevski, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters, Liesbeth C. de Wreede
Publikováno v:
European Journal of Cancer, 182, pp. 132-143
European Journal of Cancer, 182, 132-143. ELSEVIER SCI LTD
European Journal of Cancer, 182, 132-143. Pergamon
van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Manevski, D, Suijkerbuijk, K P M, Wouters, M W J M & de Wreede, L C 2023, ' Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry ', European Journal of Cancer, vol. 182, pp. 132-143 . https://doi.org/10.1016/j.ejca.2023.01.006
European Journal of Cancer, 182, 132-143
European Journal of Cancer, 182, 132-143. Elsevier Ltd.
European Journal of Cancer, 182, 132-143. ELSEVIER SCI LTD
European Journal of Cancer, 182, 132-143. Pergamon
van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Manevski, D, Suijkerbuijk, K P M, Wouters, M W J M & de Wreede, L C 2023, ' Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry ', European Journal of Cancer, vol. 182, pp. 132-143 . https://doi.org/10.1016/j.ejca.2023.01.006
European Journal of Cancer, 182, 132-143
European Journal of Cancer, 182, 132-143. Elsevier Ltd.
Introduction: When analysing patient survival, one is often interested in cause of death. Little is known about the presence of population mortality in advanced melanoma pa-tients. The aim of this study was to assess population mortality after differ